What type of study is this?

This is a Experimental Study study.

September 29, 2025Cancer Research

Abstract A094: Myofibroblast programming blocks differentiation of immune enhancing fibroblastic reticular cells in pancreatic cancer

View Full Paper

Ask AI

Bookmark

Myofibroblast programming blocks the differentiation of immune enhancing reticular cells in pancreatic cancer.
Therapeutic inhibition of TGFbR1 allowed for enhanced lymphocyte recruitment, improving T cell-dependent tumor control.
MyCAF phenotypes inhibit TLS development, indicating potential pathways to reprogramming fibroblasts in treatment.
The spatial arrangement of CAFs highlights differences between TLS-permissive and resistant pancreatic cancer models.

No takes yet. Share an insight, caveat, or question.

Research demonstrates TLS formation in pancreatic cancer is inhibited by myofibroblasts, suggesting reprogramming CAFs could enhance immunity.

Gunderson et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Research demonstrates TLS formation in pancreatic cancer is inhibited by myofibroblasts, suggesting reprogramming CAFs could enhance immunity.